Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 17/20 | 0.45 |
| ▸ | MMP13 | P45452 | 17/20 | 0.45 |
| ▸ | MMP9 | P14780 | 14/20 | 0.45 |
| ▸ | MMP14 | P50281 | 5/20 | 0.44 |
| ▸ | MMP3 | P08254 | 5/20 | 0.44 |
| ▸ | MMP8 | P22894 | 5/20 | 0.44 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096042 | 0.87 | MMP13 (0.44) | MMP2MMP13MMP9MMP14MMP3 | |
| SCHEMBL8291860 | 0.76 | AKR1C3 (0.54) | MMP2MMP13MMP9MMP14MMP3 | |
| SCHEMBL6097132 | 0.75 | ALDH1A1 (0.44) | MMP2MMP13MMP9MMP14MMP3 | |
| SCHEMBL6097160 | 0.75 | MMP2 (0.72) | MMP2MMP13MMP9MMP14MMP3 | |
| SCHEMBL6439864 | 0.74 | CYP3A4 (0.45) | MMP2MMP13MMP9MMP14 | |
| SCHEMBL4467180 | 0.72 | OPRM1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6097553 | 0.71 | TSHR (0.52) | MMP2MMP13MMP9MMP14MMP3 | |
| SCHEMBL974153 | 0.71 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6096089 | 0.71 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6096056 | 0.70 | MMP2 (0.53) | MMP2MMP13MMP9MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005106495-A1 | PROCOLLAGEN II BIOMARKERS AND METHODS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2005106495-A1 | PROCOLLAGEN II BIOMARKERS AND METHODS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | MMP14, MMP12, MMP17 | CA12 214/4885CA1 65/4885CA2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.